Gutiérrez LA, Ponte GG, Leyva QA, Valdés RM

Language: Spanish
References: 30
Page: 177-182
PDF size: 403.94 Kb.

ABSTRACT

Aldosterone is one of the components of the renin-angiotensin system. There are theoretical elements and clinical evidence of its relationship with heart diseases. Numerous bibliographic references were reviewed with the objective of describing the main characteristics of aldosterone and its relationship with these diseases. It has traditionally been thought that the action of aldosterone was restricted both, to the reabsorption of sodium and water, and to the excretion of potassium at the renal level. In recent years it has been shown to play a major role in many processes of the pathogenesis of coronary artery disease and cardiac and vascular remodeling.

REFERENCES

1. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab. 2007;18:208-14.

2. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008;57:3297-306.

3. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150:776-83.

4. Rhee SS, Pearce EN. Sistema endocrino y corazón: una revisión. Rev Esp Cardiol. 2011;64:220- 31.

5. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003;88: 2364-72.

6. Messaoudi S, Jaisser F. Aldosterone and the mineralocorticoid receptor. Eur Heart J. 2011; 13(Suppl B):4-9.

7. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013;9:459-69.

8. Messaoudi S, Azibani F, Delcayre C. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012;350:266-72.

9. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 2009;53:286- 90.

10. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33: 2782-95.

11. Rocha R. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283:H1802-10.

12. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol. 2005;186:1-20.

13. Pitt B, Stier CT, Rajagopalan S. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2003;4:164-8.

14. Contra HS, Estrada LR, Chávez, AG, Hernández H. El sistema renina-angiotensina-aldosterona y su papel funcional más allá del control de la presión arterial. Rev Mex Cardiol. 2008;19:21-9.

15. Christ M, Meyer C, Sippel K, Wehling M. Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun. 1995;213:123-9.

16. Grossmann C, Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol. 2009; 308:53-62.

17. Fuller PJ, Yao Y, Yang J, Young MJ. Mechanism of ligand specificity of the mineralocorticoid receptor. J Endocrinol. 2012;213:15-24.

18. Briet M, Schiffrin EL. Aldosterone effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6:261-73.

19. Briet M, Schiffrin EL. The role of aldosterone in metabolic syndrome. Curr Hypertens Rep. 2011; 13:163-72.

20. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are asso-ciated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010;31:1237-47.

21. Ivanes F, Susen S, Mouquet F, Pigny P, Cuilleret F, Sautičre K, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery dis-ease patients outside the setting of acute myocar-dial infarction or heart failure. Eur Heart J. 2012; 33:191-202.

22. Amano T, Matsubara T, Izawa H, Torigoe M, Yo-shida T, Hamaguchi Y, et al. Impact of plasma aldosterone levels for prediction of in-stent reste-nosis. Am J Cardiol. 2006;97:785-8.

23. De Rita O, Hackam DG, Spence JD. Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol. 2012;28:706-11.

24. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101:2981-8.

25. Leopold JA. Aldosterone, mineralocorticoid re-ceptor activation, and cardiovascular remodeling. Circulation. 2011;124:e466-8.

26. Zwadlo C, Bauersachs J. Mineralocorticoid recep-tor antagonists for therapy of coronary artery disease and related complications. Curr Opin Pharmacol. 2013;13:280-6.

27. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730-6.

28. Brilla CG, Matsubara LS, Weber KT. Anti-aldos-terone treatment and the prevention of myocar-dial fibrosis in primary and secondary hyperal-dosteronism. J Mol Cell Cardiol. 1993;25:563-75.

29. Le Menuet D, Isnard R, Bichara M, Viengchareun S, Muffat-Joly M, Walker F, et al. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid recep-tor. J Biol Chem. 2001;276:38911-20.

30. Bauersachs J. Aldosterone antagonism in heart failure: improvement of cardiac remodelling, en-dothelial dysfunction and platelet activation. Eur J Clin Invest. 2004;34:649-52.